Searchable abstracts of presentations at key conferences in endocrinology

ea0094p31 | Bone and Calcium | SFEBES2023

A single infusion of Zoledronic acid suppressed bone turnover markers for up to seven years: Results from the Zoledronate in the Prevention of Paget’s disease (ZiPP) study

Tang Jonathan , Fraser William , Phillips Jonathan , Piec Isabelle , Dunn Rachel , Keerie Catriona , Lewis Steff , Ralston Stuart , Investigators ZiPP

Zoledronate in the Prevention of Paget’s disease (ZiPP) trial (ClinicalTrials.gov ID:NCT03859895) is a multi-centre, double-blind, placebo-controlled, randomised trial of Zoledronic acid (ZA) in sequestosome1 (SQSTM1) mutation carriers. SQSTM1 mutation has high penetrance and is associated with the early onset of Paget’s disease of bone. Participants with the SQSTM1 genotype received either a single dose of IV 5mg ZA (Aclasta, Novartis); intervention group n...